Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market
1. Guggenheim initiated coverage on AMLX, seeing blockbuster potential in PBH. 2. Analyst Fernandez set a Buy rating with a $17 price target. 3. AMLX's avexitide is entering pivotal Phase 3 study, results expected by 2026. 4. Market for GLP-1 antagonists for PBH projected to exceed $2 billion by 2035. 5. AMLX stock rose 24.5% to $6.25 following the announcement.